Document is current
Any future updates will be listed below
-
Authors
Paschold, Lisa
Schultheiss, Christoph
Schmidt-Barbo, Paul
Klinghammer, Konrad
Hahn, Dennis
Tometten, Mareike
Schafhausen, Philippe
Blaurock, Markus
Brandt, Anna
Westgaard, Ingunn
Kowoll, Simone
Stein, Alexander
Hinke, Axel
Binder, Mascha
-
Funding
Funding for this research was provided by:
ULTIMOVACS
Mertelsmann Foundation
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (10.001.762)
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 21 June 2025
First Online: 5 August 2025
Competing interests
: M.Bi. received institutional research grants from Merck, BMS, Hexal, Novartis, German Cancer Aid (Krebshilfe), German Research Foundation, and the Federal Ministry of Education and Research as well as honoraria for lectures and advisory board meetings by Celgene, Janssen, Gilead, Merck, Roche, Amgen, Sanofi-Aventis and BMS. She received funding for the FOCUS trial from ULTIMOVACS. All other authors declare that they have no potential conflict of interest.
